Imiquimod Vehicle — Competitive Intelligence Brief

Imiquimod Vehicle (Imiquimod Vehicle) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Toll-like receptor agonist. Area: Dermatology/Immunology.

phase 3 Toll-like receptor agonist TLR7/TLR8 Dermatology/Immunology Small molecule

Target snapshot

Imiquimod Vehicle (Imiquimod Vehicle) — Apotex Inc.. Imiquimod vehicle is a topical formulation base designed to deliver imiquimod, a toll-like receptor 7/8 agonist that activates innate immune responses.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Imiquimod Vehicle TARGET	Imiquimod Vehicle	Apotex Inc.	phase 3	Toll-like receptor agonist	TLR7/TLR8
Zyclara®	Zyclara®	Actavis Inc.	marketed	Toll-like receptor agonist	TLR7, TLR8
Imiquimod cream + surgery	Imiquimod cream + surgery	Nantes University Hospital	phase 3	Toll-like receptor agonist (topical immune response modifier)	TLR7, TLR8
Double-Stranded RNA sodium salt	Double-Stranded RNA sodium salt	Promomed, LLC	phase 3	Toll-like receptor agonist / Immunostimulant	TLR3 (Toll-like receptor 3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Toll-like receptor agonist class)

1. Actavis Inc. · 1 drug in this class
2. Apotex Inc. · 1 drug in this class